EDIT (Editas Medicine) ROCE % : -52.91% (As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Editas Medicine ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Editas Medicine's annualized ROCE % for the quarter that ended in Dec. 2024 was -52.91%.

Editas Medicine ROCE % Historical Data

The historical data trend for Editas Medicine's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Editas Medicine ROCE % Chart

Editas Medicine Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-27.99

-33.74

-41.66

-38.01

-68.23

Editas Medicine Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															-21.73	-66.18	-84.05	-92.86	-52.91

Editas Medicine ROCE % Calculation

Editas Medicine's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-238.92	/	( ( (499.153 - 63.217)	+	(341.589 - 77.225) )	/ 2 )
	=	-238.92	/	( (435.936	+	264.364)	/ 2 )
	=	-238.92	/	350.15
	=	-68.23 %

Editas Medicine's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	-137.444	/	( ( (327.567 - 72.353)	+	(341.589 - 77.225) )	/ 2 )
	=	-137.444	/	( ( 255.214	+	264.364 )	/ 2 )
	=	-137.444	/	259.789
	=	-52.91 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Editas Medicine (NAS:EDIT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Editas Medicine ROCE % Related Terms

Thank you for viewing the detailed overview of Editas Medicine's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Editas Medicine Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Editas Medicine Inc (NAS:EDIT) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

0IFK:UK 8EM:Germany

Address

11 Hurley Street, Cambridge, MA, USA, 02141

Website

https://www.editasmedicine.com

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Executives

Baisong Mei	officer: SVP, CHIEF MEDICAL OFFICER	C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142
Gilmore Neil O'neill	director, officer: CEO	215 FIRST STREET, CAMBRIDGE MA 02142
Linda Burkly	officer: EVP, CHIEF SCIENTIFIC OFFICER	1 MAIN STREET, CAMBRIDGE MA 02142
Erick Lucera	officer: EVP, CHIEF FINANCIAL OFFICER	138 THISTLE ROAD, NORTH ANDOVER MA 08145
Jessica Hopfield	director	C/O 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Bruce Eaton	officer: EVP, Chief Business Officer	C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142
Michelle Robertson	officer: Chief Financial Officer	C/O MOMENTA PHARMACEUTICALS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Elliott M. Levy	director	C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
Mark S Shearman	officer: EVP, Chief Scientific Officer	C/O APPLIED GENETIC TECHNOLOGIES CORP, 11801 RESEARCH DRIVE, SUITE D, ALACHUA FL 32615
Lisa Anne Michaels	officer: EVP/Chief Medical Officer	C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142
Bernadette Connaughton	director	C/O VISTERRA, INC., ONE KENDALL SQUARE, #B3301, CAMBRIDGE MA 02139
James C Mullen	director	940 WINTER STREET, PERKINELMER, INC LEGAL DEPARTMENT, WALTHAM MA 02451
Emma Reeve	director	C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451
Cynthia Collins	director	65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Meeta Chatterjee	director	C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142